Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06814132 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT06814132 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 24 participants.
The verdict
NCT06814132, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time. Researchers will compare what happens to MK-5684 after hemodialysis in people with severe renal impairment and end-stage renal disease versus healthy people.
Interventions
- DRUG Prednisone
- DRUG Fludrocortisone acetate
- DRUG MK-5684
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2025-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06814132
The ClinicalTrials.gov registry entry for NCT06814132 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT06814132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06814132 about?
NCT06814132 is a clinical study titled "A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)". The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time. Researchers will compare what happens to MK-5684 after hemodialysis in people with severe renal impairment and end-stage re...
What is the current status of trial NCT06814132?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-04-07. Estimated completion is 2025-10-14.
What interventions are being tested in trial NCT06814132?
The interventions under investigation include: Prednisone (DRUG), Fludrocortisone acetate (DRUG), MK-5684 (DRUG).
Who is sponsoring clinical trial NCT06814132?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.